<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77132">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01774045</url>
  </required_header>
  <id_info>
    <org_study_id>Phase I  study of PDC-1421</org_study_id>
    <nct_id>NCT01774045</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression</brief_title>
  <official_title>A Dose Escalation Phase I Study of PDC-1421 Capsule to Evaluate the Safety in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioLite, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioLite, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Taiwan : Food and Drug Administration</authority>
    <authority>Taiwan: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of PDC-1421 Capsule in healthy subject,
      find the effective adequate dose for the next stage of the study, and accumulate information
      of possible mechanism of its anti-depressive effect.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
  <primary_outcome>
    <measure>Physical examination, Vital sign, ECG, Hematology, Blood chemistry, AEs/SAEs monitoring, C-SSRS</measure>
    <time_frame>observe for 72hr after taking drugs</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety endpoint is based on the measurement of physical examination, vital signs,laboratory data, Electrocardiograph(ECG), Columbia-Suicide Severity Rating Scale (C-SSRS) evaluation and number of adverse events(AEs) and serious adverse events (SAEs) during the study period.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>PDC-1421</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage form: 380mg PDC-1421 per Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosage form: Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDC-1421</intervention_name>
    <arm_group_label>PDC-1421</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 20-65 years.

          2. Subjects must be able to understand and willing to sign informed consent.

          3. Female subjects of child-bearing potential must test negative to pregnancy and use
             appropriate birth control method from the beginning of study to the 15 days later
             after ending of study.

          4. Laboratory data: red blood cell count(RBC),white blood cell count(WBC), platelets,
             hematocrit, hemoglobin, prothrombin time(PT), partial thromboplastin time
             (aPTT),aspartate transaminase(AST),alanine aminotransferase(ALT), Lactate
             dehydrogenase(LDH), total bilirubin, blood urea nitrogen(BUN),serum creatinine, free
             thyroxine (FT4), thyroid-stimulating hormone (TSH) level,sodium, potassium, calcium,
             glucose, are all within the normal range.

          5. No significantly abnormal findings on physical examination, ECG and vital sign.

        Exclusion Criteria:

          1. With any clinically significant neurological, gastrointestinal, renal,
             hepatic,cardiovascular, respiratory, metabolic, endocrine, hematological or other
             major disorders as determined by the Investigator.

          2. A positive drug screen.

          3. Any mental disorder diagnosed by board-certificated psychiatrist through detailed
             diagnostic interview.

          4. Any history of suicidal behavior in the past 6 months when evaluated by the C-SSRS.

          5. The intensity of suicidal ideation in the past 6 months is no less than 4 defined by
             the C-SSRS.

          6. Have received any prescribed medicine, investigational drug or any non prescribed
             medicine (including herbal remedies) with 14 days prior to enroll this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheng-Ta Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tung-Ping Su, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hsien-Ming Wu</last_name>
      <phone>886-3-578-6976</phone>
      <phone_ext>11</phone_ext>
      <email>sonnywu@bioliteinc.com</email>
    </contact>
    <contact_backup>
      <last_name>Yu-Han Lee</last_name>
      <phone>886-2-8751-8701</phone>
      <phone_ext>22</phone_ext>
      <email>lauryn1022@bioliteinc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Cheng-Ta Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tung-Ping Su, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 24, 2013</lastchanged_date>
  <firstreceived_date>January 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major depressive disorder</keyword>
  <keyword>Depression</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
